Our experience with
Wobenzym in the treatment of patients with rheumatoid and psoriatic
arthritis.
Szilasiová A., Macejová Ž., Jautová
J., Pundová L. Our experience with Wobenzym in the treatment of
patients with rheumatoid and psoriatic arthritis. Prakt. Lékař
1998, Vol. 78, No. 7, pp. 366-368.
Summary: The objective of the uncontrolled trial was to
assess the tolerance and safety of the preparation Wobenzym in
patients with rheumatoid and psoriatic arthritis who had other
concurrent anti-inflammatory treatment and to evaluate its position
in combined treatment of RA and PsA. The authors added Wobenzym, 9
to 15 enterosolvent pills per day to anti-inflammatory antirheumatic
treatment in 23 patients with RA and 4 patients with PsA because of
persisting clinical and laboratory activity. Treatment lasted 16
weeks and more. The evaluation of the effectiveness of Wobenzym by
the physician was as follows: very good 33.3 %, good 54.3 % and
unsatisfactory 12.4 %. The evaluation of physical capacity by the
patients was as follows: 18 patients (75 %) reported a better
physical capacity after Wobenzym and only 25 % (6) had the same
physical capacity. There was no case of deterioration. When
evaluating clinical parameters, the authors found after four months
of treatment a decline of the morning stiffness (p < 0.01) and a
better grip strength (p < 0.05), reduced articular index and index
of incapacity according to HAQ, which however was not statistically
significant. The authors recorded a decline of FW the CRP and CIK
concentration (p < 0.01). The concentration of alpha-2
macroglobulin, alpha-1 antitrypsin, haemoglobin and amylase values
did not change significantly during treatment. The trial confirmed
the favourable effect of Wobenzym on the rheumatic process, good
tolerance and safety of treatment in patients with rheumatoid
diseases even in case of polytherapy.
Key words: Wobenzym - enzyme therapy - rheumatoid arthritis -
psoriatic arthritis.
